Spero Therapeutics (SPRO) Liabilities and Shareholders Equity (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $59.0 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 24.05% year-over-year to $59.0 million; the trailing twelve-month figure through Mar 2026 stood at $244.2 million (down 48.4% YoY), and the FY2025 full-year result was $68.9 million, down 37.65% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $59.0 million, down from $68.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $182.4 million in Q4 2023 and bottomed at $54.2 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $107.1 million (2023), against an average of $105.0 million.
• The widest annual swing landed in 2023, when Liabilities and Shareholders Equity soared 66.11%; it then plunged 59.92% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $124.8 million in 2022, then soared by 46.14% to $182.4 million in 2023, then slumped by 39.39% to $110.5 million in 2024, then plunged by 37.65% to $68.9 million in 2025, then fell by 14.36% to $59.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $59.0 million (Q1 2026), $68.9 million (Q4 2025), and $54.2 million (Q3 2025), per Business Quant data.

Peer Comparison